NextCure, Inc. - NXTC STOCK NEWS

NextCure has published preclinical data on NC410, a novel immunomedicine targeting collagen-rich tumors, in the journal eLife. This treatment, currently in a Phase 1/2 clinical trial for advanced solid tumors, aims to block immune suppression via LAIR-1. Preclinical studies show that NC410 promotes T cell activity and may be effective as a monotherapy or in combination with checkpoint inhibitors. Initial clinical data is expected in the second half of 2021, offering potential hope for patients with resistant cancers.

NextCure, Inc. (Nasdaq: NXTC) announced its participation in a fireside chat at the JMP Securities Life Sciences Conference on June 17 at 1:30 pm Eastern time. Interested investors can access the live audio webcast on its website, with a replay available afterward for 30 days. NextCure is focused on developing first-in-class immunomedicines to treat cancer and other immune-related diseases through its proprietary FIND-IO™ platform, aiming to provide new treatments for patients resistant to current therapies.

NextCure, a clinical-stage biopharmaceutical company, announced that Dr. Martin Gutierrez will present a Trials in Progress poster for NC410 at the 2021 ASCO Annual Meeting. NC410 targets collagen-rich areas in tumors, acting as a LAIR-1 decoy to enhance immune responses. Preliminary studies indicate significant anti-tumor activity across multiple cancer types, including gastric and ovarian cancers. The Phase 1/2 study aims to assess safety and preliminary efficacy, with initial clinical data expected in late 2021.

NextCure, Inc. (Nasdaq: NXTC) reported its Q1 2021 financial results, showing a net loss of $16.5 million compared to a net income of $9.7 million in Q1 2020. The company’s cash reserves decreased to $268.2 million, down from $283.4 million at year-end 2020, impacted by operational expenditures. Notably, no revenue was generated in Q1 2021, a decline from $22.4 million the previous year. The company remains focused on its clinical programs, with ongoing trials for NC318, NC410, and NC762, and expects to fund operations into the second half of 2023.

NextCure, a clinical-stage biopharmaceutical company (Nasdaq: NXTC), will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 12 at 2:00 pm ET. The event will showcase NextCure's commitment to developing innovative immunomedicines for cancer and immune-related diseases, leveraging their proprietary FIND-IO™ platform. A live audio webcast will be accessible via their website, with a replay available for 30 days post-event.

NextCure, Inc. (Nasdaq: NXTC) announced its participation in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5th at 2:40 PM Eastern time. The event will be accessible via a live audio webcast on the company’s website, with a replay available for 30 days post-event.

NextCure focuses on developing first-in-class immunomedicines for cancer and immune-related diseases using its FIND-IO™ platform. The company aims to provide new treatments for patients unresponsive to existing therapies.

NextCure (Nasdaq: NXTC) presented preclinical data for its investigational monoclonal antibody NC762 at the AACR Annual Meeting 2021. NC762 targets B7-H4, showing promising anti-tumor properties and inhibiting tumor growth in various cancer models. Key findings include a mechanism of action independent from T cells and NK cells, allowing for enhanced anti-tumor activity. IND-enabling studies showed a favorable safety profile and half-life of 8-10 days. NextCure plans to advance NC762 into clinical trials this quarter, aiming to expand its innovative immunomedicine pipeline.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, announced its participation in the 20th Annual Needham Virtual Healthcare Conference on April 13 at 12:45 PM Eastern Time. The company focuses on developing first-in-class immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform. A live audio webcast will be accessible on the company's website, with a replay available for 30 days post-event.

NextCure, Inc. (Nasdaq: NXTC) reported its financial results for Q4 and full year 2020, including a net loss of $36.6 million for the year, reflecting a rise in R&D and G&A expenses. Cash reserves decreased from $334.6 million in 2019 to $283.4 million in 2020. Despite challenges from the COVID-19 pandemic, the company is advancing clinical trials for NC318, including a Phase 2 trial planned at Yale University. NextCure is also preparing to initiate trials for NC762 and anticipates sharing initial data for NC410 in the second half of 2021.